Propulsid Physician Education On Cardiac Risk To Be Presented To Committee
Executive Summary
Janssen will detail professional education campaign plans for conveying cardiac risks associated with the nighttime heartburn treatment Propulsid (cisapride) at the April 12 FDA advisory committee review of the product's safety.
You may also be interested in...
Propulsid Limited Access Program Allows Off-Label Use To Continue
FDA and Johnson & Johnson are indicating that the new Propulsid limited access program will allow physicians to continue prescribing the drug for more serious conditions than nocturnal heartburn due to gastroesophageal reflux disease, the labeled indication.
Propulsid Limited Access Program Allows Off-Label Use To Continue
FDA and Johnson & Johnson are indicating that the new Propulsid limited access program will allow physicians to continue prescribing the drug for more serious conditions than nocturnal heartburn due to gastroesophageal reflux disease, the labeled indication.
J&J, Lilly & Merck Reassure Investors About Medicare Reform Process
The lessons from the health care reform debate in the mid-1990s will ensure a more "sensible" debate over health care in 2000, J&J CEO Ralph Larsen told analysts during a Jan. 25 conference call.